YGYuliya I. Gusel'NIkova

Yuliya I. Gusel'NIkova

*This is an algorithmically generated author record based on publicly available information.

Yuliya I. Gusel'NIkova has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PREVALENCE AND CLINICAL SIGNIFICANCE OF IRON DEICIENCY IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE: RESULTS OF A SINGLE-CENTER COHORT STUDY

    by Yulia I. Guselnikova, Тамара Борзалиевна Печерина, Елена Владимировна Дрень, Маргарита Николаевна Синькова, Ольга Леонидовна Барбараш

    Highlights Iron deficiency is one of the most common comorbidities in heart failure, associated with a negative prognosis; however, the significance of iron deficiency in patients with acute decompensated heart failure remains uncertain. The obtained results allowed us to expand the profile of patients with acute decompensated heart failure and evaluate the contribution of iron deficiency to the course of the disease and the long-term prognosis of patients. Aim . To determine the prevalence of iron deficiency (ID), to assess its clinical and prognostic significance, and its impact on one-year outcomes in patients with acute decompensated heart failure, based on data from a single-center cohort study. Methods. This prospective cohort study consecutively (from January 1, 2023 to January 1, 2024) included 812 patients admitted with acute decompensated heart failure. The observation period was from January 1, 2023 to January 1, 2025, inclusive. The median age was 72 [57; 83] years. Results. The clinical phenotypes of patients with ADHF were predominantly represented by an ischemic origin of heart failure. All patients with ADHF had a high prevalence of hypertension and a high Charlson comorbidity index. It was found that patients with ID had significantly higher NT-proBNP values than patients without ID: 2810.8 [1 783.6; 4 198.3] versus 1 981.2 [1 221.5; 3 241.7] pg/ml. Patients with ID had a higher prevalence of major underlying diseases: type 2 diabetes (n = 181, 37.0% vs n = 102, 31.5%; p < 0.05), obesity (n = 378, 77.3% vs n = 170, 52.6%, p < 0.05), CKD (n = 263, 53.9% vs n = 144, 44.5%, p < 0.05); as well as older age (76 [54; 83] vs 69 [47; 79] years). The total number of adverse events was higher in the group of patients with ID. Conclusions. The prevalence of iron deficiency in patients with ADHF was 60%. Patients with ID were characterized by older age, a high prevalence of type 2 diabetes, obesity, and CKD, as well as a greater number of adverse events during the long-term follow-up period.

  • Prevalence of iron deficiency in patients with acute decompensated heart failure

    by Yu. I. Gusel’NIkova, T. B. Pecherina, O. L. Barbarash

    Aim. The research aims to systematize current data on the prevalence, diagnosis, and clinical significance of iron deficiency (ID) in patients with acute decompensated heart failure (ADHF). Materials and methods. A systematic analysis of studies from 2019 to 2024 in PubMed and eLibrary databases was conducted, including data from 6,500 patients with ADHF. Selection criteria were as follows: confirmed ADHF diagnosis, assessment of iron status using standard parameters (ferritin and transferrin saturation (TSAT)), and availability of clinical outcome data. Results: To differentiate the type of iron deficiency, optimal diagnostics of simultaneous assessment of ferritin and TSAT levels requires: ferritin < 100 μg/L – absolute ID; ferritin 100–299 μg/L in combination with TSAT < 20% – functional ID. ID was found in 45–89% of ADHF patients and was associated with: more severe disease progression (functional class III-IV according to the New York Heart Association system in 68% of cases), elevated of N-terminal propeptide of type B natriuretic peptide levels (35% higher compared to non-ID patients), reduced exercise tolerance (six-minute walk test: 278±45 m vs 342±38 m in non-ID group). Conclusion: Iron deficiency is an independent prognostic factor in ADHF. Early diagnosis and correction, particularly through intravenous ferric carboxymaltose administration, may improve clinical outcomes and reduce hospital readmission rates.

  • ACUTE HEART FAILURE AND DECOMPENSATED HEART FAILURE: THE IMPORTANCE OF MULTIMORBIDITY (LITERATURE REVIEW)

    by Tamara B. Pecherina, Margarita N. Sinkova, Yulia I. Guselnikova, Olga L. Barbarash

    Highlights Understanding the interaction between various diseases in patients with acute heart failure and acute decompensated heart failure is key to developing effective prevention and management strategies aimed at improving the quality of medical care and reducing morbidity and mortality among this group of patients. Abstract Acute decompensated heart failure (ADHF) is a serious clinical condition that is often accompanied by multimorbidity, i.e. the presence of several chronic diseases simultaneously. These comorbidities significantly complicate the diagnosis, treatment and prognosis of outcomes in patients with ADHF. The review considers the most common comorbid conditions, such as arterial hypertension, diabetes mellitus, chronic kidney disease, obesity, depression and cognitive impairment. Each of these factors individually, as well as together (synergistically), affects the course of ADHF, increasing the risk of complications and worsening the patient's quality of life. Emphasizes the importance of an integrated approach to the management of patients with ADHF and multimorbidity. Early detection and pathogenetic therapy of comorbidities can reduce the frequency of hospitalizations, improve the functional capabilities of patients and increase life expectancy. Thus, understanding the interactions between various diseases in patients with ADHF is key to developing effective prevention and treatment strategies aimed at improving the quality of medical care and reducing morbidity and mortality in this group of patients.


  • Open Access

    10-year experience in orthotopic heart transplantation in Kuzbass

    by L. S. Barbarash, O. L. Barbarash, E. V. Grigoriev, D. L. Shukevich, T. B. Pecherina, M. G. Zinets, A. V. Sotnikov, I. K. Khalivopulo, T. S. Golovina, E. M. Kurguzova, et al.

    Десятилетний опыт ортотопической трансплантации сердца в Кузбассе


  • Open Access

    Clinical and anamnestic characteristics of patients depending on left ventricular ejection fraction: results of a register study

    by P. G. Parfenov, A. V. Yurkina, D. P. Golubovskaya, S. Y. Shuster, Е. В. Дрень, Y. I. Guselnikova, N. B. Lebedeva, T. B. Pecherina

    Aim. To study the clinical and anamnestic features of patients followed up in the Center for Chronic Heart Failure at the Regional Vascular Center according to the data of the corresponding register.Materials and methods. The study included data of 802 patients included in the Kuzbass Register of Patients Followed up at the Center for Chronic Heart Failure from 2020 to 2022. The median follow-up was 1.6 ± 0.7 years. Results. According to the present register, men dominated in the gender profile of patients with chronic heart failure – 612 (76.3%) participants (p < 0.001). The largest group of subjects was represented by patients with a low left ventricular ejection fraction (less than 40%) – 546 people. This category was also characterized by a more severe functional class of chronic heart failure (New York Heart Association); patients with functional class III– IV chronic heart failure prevailed (p < 0.001). The most common comorbidities revealed were chronic kidney disease (glomerular filtration rate of less than 60 ml / min / 1.73 m2 according to the CKD-EPI equation) – 614 (76.5%) patients and obesity (body mass index of more than 30 kg / m2) – 334 (41.6%) patients. Type 2 diabetes mellitus was reported in 193 (24%) patients. The analysis of the etiology of chronic heart failure showed that the main causes of heart failure in the groups with low and intermediate left ventricular ejection fraction were coronary heart disease and combined causes, whereas in the group with preserved left ventricular ejection fraction, the disease resulted from coronary heart disease and arrhythmogenic causes. Conclusion. Assessing the clinical and anamnestic features of patients with heart failure, it can be said that these people are mainly male, retired, with coronary heart disease, low left ventricular ejection fraction, and a comorbidity, mainly chronic kidney disease, diabetes mellitus, and obesity.


  • Open Access

    NEW BIOLOGICAL MARKERS FOR A PROGNOSTIC MODEL FOR ASSESSING THE RISK OF CARDIAC FIBROSIS IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

    by Tamara B. Pecherina, Victoria N. Karetnikova, Vasily V. Kashtalap, Elena V. Dren’, Julia S. Ignatova, Sophia Yu. Shuster, Anastasia V. Yurkina, Yuliya I. Gusel'NIkova, Olga L. Barbarash

    HighlightsThe developed prognostic model for assessing the risk of cardiac fibrosis in patients with STEMI with HFmrEF and HFpEF is promising from the point of view of scientific and clinical potential because similar models for predicting the risk of cardiac fibrosis in patients with index MI are not currently validated. The developed scale includes such parameters as age, LVEF, COL-1, BMI, MMP-2. The scale can be used in patients with HFmrEF and HFpEF phenotypes. Identification of patients at high risk of myocardial fibrosis will allow choosing the appropriate treatment method. Aim. To develop a prognostic model for assessing the risk of cardiac fibrosis (CF) in patients with preserved left ventricular ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF) a year after ST-segment elevation myocardial infarction (STEMI) based on clinical, instrumental and biochemical data.Methods. The prospective cohort study included 100 STEMI patients with HFmrEF (LVEF 40–49%) and with HFpEF (50% or more). Echo was performed in all patients on the 1st, 10–12th day and a year after onset of STEMI. Upon admission to the hospital and on the 10–12th day after the onset of the disease, the following serum biomarker levels were determined: those associated with changes in the extracellular matrix; with remodeling and fibrosis; with inflammation, and with neurohormonal activation. At the 1-year follow-up visit, 84 patients underwent contrast-enhanced MRI to assess fibrotic tissue percentage relative to healthy myocardium.Results. The distribution of patients by HFmrEF and HFpEF phenotypes during follow-up was as follows: HFmrEF on the 1st day – 27%, 10th day – 12%, after a year – 11%; HFpEF on the 1st day – 73%, 10th day – 88%, after a year – 89%. According to cardiac MRI at the follow-up visit (n = 84), the median distribution of fibrotic tissue percentage was 5 [1.5; 14]%. Subsequently, the threshold value of 5% was chosen for analysis: CF≥5% was found in 38 patients (the 1st group), whereas CFnd group). When analyzing the intergroup differences in biological marker concentrations in the in-patient setting and at the annual follow-up, it was determined that the most significant differences were associated with “ST-2” (1st day) that in the “CF≥5%” group was 11.4 ng/mL higher on average compared to the “CFst day) that in the “CF≥5%” group was 28112.3 pg/mL higher on average compared to the “CFth day) that in the “CFth day), collagen-1 (1st and 12th day), body mass index, matrix metalloproteinase-2 (12th day) were determined and included in the prognostic model for assessing the risk of CF a year after the STEMI (AUC ROC 0.90, Chi-square test Conclusion. Prognostic model (scale) based on factors such as age, left ventricular ejection fraction (12th day), collagen-1 (1st and 12th day), body mass index, matrix metalloproteinase-2 (12th day) shows high prognostic power and enables identification of patients with HFmrEF and HFpEF phenotypes and at high risk of cardiac fibrosis a year after STEMI.